Cindy E Neunert1, Brianna C Bright, George R Buchanan. 1. Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA. cindy.neunert@utsouthwestern.edu
Abstract
BACKGROUND: Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized. PROCEDURE: We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting. RESULTS: Two hundred and ninety-seven surveys (35% response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67% reported that they would instead treat with rituximab. If initial drug therapy failed, 47% would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001). CONCLUSIONS: Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized. PROCEDURE: We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting. RESULTS: Two hundred and ninety-seven surveys (35% response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67% reported that they would instead treat with rituximab. If initial drug therapy failed, 47% would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001). CONCLUSIONS: Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices. (c) 2008 Wiley-Liss, Inc.
Authors: Rachael F Grace; Jenny M Despotovic; Carolyn M Bennett; James B Bussel; Michelle Neier; Cindy Neunert; Shelley E Crary; Yves D Pastore; Robert J Klaassen; Jennifer A Rothman; Kerry Hege; Vicky R Breakey; Melissa J Rose; Kristin A Shimano; George R Buchanan; Amy Geddis; Kristina M Haley; Adonis Lorenzana; Alexis Thompson; Michael Jeng; Ellis J Neufeld; Travis Brown; Peter W Forbes; Michele P Lambert Journal: Am J Hematol Date: 2018-05-06 Impact factor: 10.047
Authors: Rachael F Grace; Carolyn M Bennett; A Kim Ritchey; Michael Jeng; Courtney D Thornburg; Michele P Lambert; Michelle Neier; Michael Recht; Manjusha Kumar; Victor Blanchette; Robert J Klaassen; George R Buchanan; Margaret Heisel Kurth; Diane J Nugent; Alexis A Thompson; Kimo Stine; Leslie A Kalish; Ellis J Neufeld Journal: Pediatr Blood Cancer Date: 2011-06-14 Impact factor: 3.167
Authors: James H Wood; David A Partrick; Taru Hays; Angela Sauaia; Frederick M Karrer; Moritz M Ziegler Journal: Pediatr Surg Int Date: 2011-05-28 Impact factor: 1.827
Authors: Karen K W Wang; Cathy Charles; Nancy M Heddle; Emmy Arnold; Laura Molnar; Donald M Arnold Journal: Health Expect Date: 2012-08-07 Impact factor: 3.377
Authors: Brigitta U Mueller; Carolyn M Bennett; Henry A Feldman; James B Bussel; Thomas C Abshire; Theodore B Moore; Hadi Sawaf; Mignon L Loh; Zora R Rogers; Bertil E Glader; Maggie C McCarthy; Donald H Mahoney; Thomas A Olson; Stephen A Feig; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Ellis J Neufeld Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.167